There has recently been a paradigm shift in advanced melanoma management with the development of two new classes of drugs. The two drugs currently in clinical trials are the biggest ever development in the medical management of melanoma.
The BRAF mutation causes cells to proliferate without any control or normal programmed cell death (apoptosis). Approximately 50% of melanoma cells have the mutated BRAF gene. It is more common in the young and more likely present in metastatic disease compared with primary melanoma.